Ramin Rak performs a number of procedures intended to treat diseases affecting the brain and spine.
As a board certified neurosurgeon at Neurological Surgery, P.C., he has encountered many patients who require Glioblastoma Treatment. According to the American Brain Tumor Association, Glioblastomas (GBM) are highly malignant tumors that arise from cells that make up brain tissue. Unfortunately, treatment is difficult, as the cells reproduce very quickly and are supported by a large network of blood vessels.
Ramin Rak has developed a reputation as an expert in microneurosurgical techniques, including treating GBM patients.
More of Ramin Rak’s impressive credentials can be found on ExpertFile. Recently, encouraging research has surfaced that will aid in the treatment of glioblastomas. According to an article in NewsMedical, researchers in California have identified a new biological marker that can predict whether glioblastoma will respond to chemotherapy. A biological marker, or biomarker, is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.”
Patients with Glioblastoma often undergo a combination of treatments, including chemotherapy.
Every patient diagnosed receives a type of chemotherapy called temozolomide, which is accompanied with risks and side effects. The study’s principal investigator Clark C. Chen, MD, PhD, claims that patients should not undergo therapies if there’s no likelihood of benefit. Fortunately, with this new biomarker, doctors can identify whether patients will benefit from temozolomide or should consider alternative treatment.
Researchers studied levels of MGMT, which is a protein that lessens the effect of temozolomide.
If patients have a tumor with high levels of MGMT, it is likely they will have a poor response to the chemotherapy. Scientists also discovered that they could increase the tumor’s sensitivity to chemotherapy by injecting MGMT-regulating microRNAs into glioblastoma cells. With these promising new findings, researchers are hopeful that more glioblastoma patients will derive long-lasting benefits of temozolomide.